For research use only. Not for therapeutic Use.
Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections[1][2].
Gremubamab (1, 5, 15 mg/kg; i.v.; at 1 h postinfection) improves survival outcomes in rabbit acute pneumonia model[2].
| Catalog Number | I041844 |
| CAS Number | 1800381-36-5 |
| Purity | ≥95% |
| Reference | [1]. Chastre J, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022 Nov 15;26(1):355. [2]. Le HN, et al. Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00710-19. |
